Compare SCYX & MXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCYX | MXE |
|---|---|---|
| Founded | 1999 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.4M | 59.7M |
| IPO Year | 2014 | 1994 |
| Metric | SCYX | MXE |
|---|---|---|
| Price | $4.44 | $13.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 64.8K | 4.5K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 2.66% |
| EPS Growth | ★ 61.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $608.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $11.11 |
| 52 Week High | $6.09 | $14.30 |
| Indicator | SCYX | MXE |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 47.69 |
| Support Level | $0.67 | $12.69 |
| Resistance Level | $5.56 | $13.86 |
| Average True Range (ATR) | 0.34 | 0.30 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 0.63 | 34.47 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.